ATE214924T1 - Verwendung von nebivolol als anti-atherogenisches mittel - Google Patents
Verwendung von nebivolol als anti-atherogenisches mittelInfo
- Publication number
- ATE214924T1 ATE214924T1 AT95942209T AT95942209T ATE214924T1 AT E214924 T1 ATE214924 T1 AT E214924T1 AT 95942209 T AT95942209 T AT 95942209T AT 95942209 T AT95942209 T AT 95942209T AT E214924 T1 ATE214924 T1 AT E214924T1
- Authority
- AT
- Austria
- Prior art keywords
- atherogeneic
- nebivolol
- agent
- alpha
- chromanmethanol
- Prior art date
Links
- KOHIRBRYDXPAMZ-YHBROIRLSA-N (S,R,R,R)-nebivolol Chemical compound C1CC2=CC(F)=CC=C2O[C@H]1[C@H](O)CNC[C@@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 KOHIRBRYDXPAMZ-YHBROIRLSA-N 0.000 title 1
- 229960000619 nebivolol Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 210000000653 nervous system Anatomy 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000036542 oxidative stress Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP94203775 | 1994-12-28 | ||
| PCT/EP1995/005174 WO1996019987A1 (en) | 1994-12-28 | 1995-12-21 | Use of nebivolol as an anti-atherogenic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE214924T1 true ATE214924T1 (de) | 2002-04-15 |
Family
ID=8217503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95942209T ATE214924T1 (de) | 1994-12-28 | 1995-12-21 | Verwendung von nebivolol als anti-atherogenisches mittel |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US5874461A (de) |
| EP (1) | EP0801564B1 (de) |
| JP (1) | JPH10511655A (de) |
| KR (1) | KR100264348B1 (de) |
| CN (1) | CN1167418C (de) |
| AT (1) | ATE214924T1 (de) |
| AU (1) | AU700364B2 (de) |
| CA (1) | CA2207333C (de) |
| CZ (1) | CZ287513B6 (de) |
| DE (1) | DE69526120T2 (de) |
| DK (1) | DK0801564T3 (de) |
| ES (1) | ES2176354T3 (de) |
| FI (1) | FI118884B (de) |
| HU (1) | HU226208B1 (de) |
| NO (1) | NO315687B1 (de) |
| NZ (1) | NZ298074A (de) |
| PT (1) | PT801564E (de) |
| SI (1) | SI0801564T1 (de) |
| SK (1) | SK282144B6 (de) |
| WO (1) | WO1996019987A1 (de) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100264348B1 (ko) * | 1994-12-28 | 2000-08-16 | 디르크 반테 | 항-죽종형성제로서 네비볼롤을 함유하는 조성물 |
| DE19716120A1 (de) * | 1997-04-17 | 1998-10-22 | Europ Lab Molekularbiolog | Verwendung von cholesterinsenkenden Mitteln |
| US6713651B1 (en) | 1999-06-07 | 2004-03-30 | Theravance, Inc. | β2-adrenergic receptor agonists |
| US6541669B1 (en) | 1998-06-08 | 2003-04-01 | Theravance, Inc. | β2-adrenergic receptor agonists |
| JP2000207219A (ja) * | 1999-01-18 | 2000-07-28 | Fujitsu Ten Ltd | 車載端末とセンタ―との間の通信システム、及び、通信システムに使用する車載端末 |
| US6683115B2 (en) | 1999-06-02 | 2004-01-27 | Theravance, Inc. | β2-adrenergic receptor agonists |
| US6593497B1 (en) | 1999-06-02 | 2003-07-15 | Theravance, Inc. | β2-adrenergic receptor agonists |
| UA73965C2 (en) | 1999-12-08 | 2005-10-17 | Theravance Inc | b2 ADRENERGIC RECEPTOR ANTAGONISTS |
| DE60233140D1 (de) | 2001-05-02 | 2009-09-10 | Nitromed Inc | Nitrosiertes und nitrosyliertes nebivolol und seine metaboliten, zusammensetzungen und anwendungsverfahren |
| AU2003287250B9 (en) * | 2002-10-30 | 2010-01-28 | Ptc Therapeutics, Inc. | Identifying therapeutic compounds based on their physical-chemical properties |
| ITTO20030140U1 (it) * | 2003-09-16 | 2005-03-17 | Interfila Srl | Matita cosmetica |
| CA2583087C (en) * | 2003-09-19 | 2012-07-10 | Galileo Pharmaceuticals, Inc. | Chroman derivatives |
| US7803838B2 (en) | 2004-06-04 | 2010-09-28 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
| US7838552B2 (en) | 2004-06-04 | 2010-11-23 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
| MX2007000911A (es) | 2004-07-30 | 2007-04-12 | Torrent Pharmaceuticals Ltd | Nevibolol y sus sales farmaceuticamente aceptables, proceso para su preparacion y composiciones farmaceuticas de nevibolol. |
| AP2764A (en) * | 2005-01-31 | 2013-09-30 | Mylan Lab Inc | Hydroxylated nebivolol metabolites |
| PL1888059T3 (pl) | 2005-06-01 | 2015-06-30 | Bioelectron Tech Corp | Środki terapeutyczne aktywne wobec układów redoks do leczenia chorób mitochondrialnych i innych zaburzeń oraz modulacja biomarkerów energetycznych |
| JP5374162B2 (ja) | 2006-02-22 | 2013-12-25 | エジソン ファーマシューティカルズ， インコーポレイテッド | ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節 |
| EP2220030B1 (de) | 2007-11-06 | 2016-01-13 | Edison Pharmaceuticals, Inc. | 4-(p-chinonyl)-2-hydroxybutanamidderivate zur behandlung von mitochondrialen krankheiten |
| WO2009091777A1 (en) * | 2008-01-15 | 2009-07-23 | Forest Laboratories Holdings Limited | Nebivolol in the treatment of sexual dysfunction |
| JP5710277B2 (ja) | 2008-03-05 | 2015-04-30 | エジソン ファーマシューティカルズ， インコーポレイテッド | 酸化ストレス疾患の処置のための２−置換−ｐ−キノン誘導体 |
| MX2011002318A (es) | 2008-09-10 | 2011-05-10 | Edison Pharmaceuticals Inc | Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox. |
| WO2010045220A1 (en) | 2008-10-14 | 2010-04-22 | Edison Pharmaceuticals, Inc. | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
| MX2011006549A (es) * | 2008-12-19 | 2011-07-20 | Schering Corp | Suplemento alimenticio para el cultivo de celula de mamifero y metodos de uso. |
| EP2424495B1 (de) | 2009-04-28 | 2018-01-17 | Bioelectron Technology Corporation | Behandlung von erblicher leber-optikus-neuropathie und dominanter optikus-neuropathie mit tocotrienol-chinonen |
| US20130065910A1 (en) * | 2010-06-04 | 2013-03-14 | Comprehensive Drug Enterprises Ltd. | Oral meclizine aqueous formulations with taste flavoring agent |
| US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
| US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
| DE102014107132A1 (de) | 2014-05-20 | 2015-11-26 | Corden Pharma International Gmbh | Verfahren zur Herstellung von Epoxiden die in der Herstellung von Nebivolol und dessen Derivaten einsetzbar sind |
| WO2016062272A1 (zh) * | 2014-10-24 | 2016-04-28 | 朗齐生物医学股份有限公司 | 免疫疾病用药物在制备抑制癌症的医药组合物中的应用 |
| PT3233786T (pt) | 2014-12-16 | 2022-05-06 | Ptc Therapeutics Inc | Formas polimórficas e amorfas de (r)-2-hidroxi-2-metil-4- (2,4,5-trimetil-3,6-dioxociclohexa-1,4-dienil)butanamida |
| CA3008849A1 (en) | 2015-12-17 | 2017-06-22 | Bioelectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1337432C (en) * | 1988-03-23 | 1995-10-24 | Raymond M. Xhonneux | Method of lowering the blood pressure |
| TW355683B (en) * | 1994-02-17 | 1999-04-11 | Janssen Pharmaceutica Nv | Composition containing micronized nebivolol |
| KR100264348B1 (ko) * | 1994-12-28 | 2000-08-16 | 디르크 반테 | 항-죽종형성제로서 네비볼롤을 함유하는 조성물 |
-
1995
- 1995-12-21 KR KR1019970703648A patent/KR100264348B1/ko not_active IP Right Cessation
- 1995-12-21 JP JP8520223A patent/JPH10511655A/ja active Pending
- 1995-12-21 NZ NZ298074A patent/NZ298074A/xx not_active IP Right Cessation
- 1995-12-21 WO PCT/EP1995/005174 patent/WO1996019987A1/en active IP Right Grant
- 1995-12-21 PT PT95942209T patent/PT801564E/pt unknown
- 1995-12-21 AU AU43477/96A patent/AU700364B2/en not_active Expired
- 1995-12-21 CZ CZ19971919A patent/CZ287513B6/cs not_active IP Right Cessation
- 1995-12-21 EP EP95942209A patent/EP0801564B1/de not_active Expired - Lifetime
- 1995-12-21 CN CNB951971492A patent/CN1167418C/zh not_active Expired - Lifetime
- 1995-12-21 CA CA002207333A patent/CA2207333C/en not_active Expired - Fee Related
- 1995-12-21 US US08/860,238 patent/US5874461A/en not_active Expired - Lifetime
- 1995-12-21 SI SI9530591T patent/SI0801564T1/xx unknown
- 1995-12-21 SK SK856-97A patent/SK282144B6/sk not_active IP Right Cessation
- 1995-12-21 ES ES95942209T patent/ES2176354T3/es not_active Expired - Lifetime
- 1995-12-21 DE DE69526120T patent/DE69526120T2/de not_active Expired - Lifetime
- 1995-12-21 AT AT95942209T patent/ATE214924T1/de active
- 1995-12-21 HU HU9800675A patent/HU226208B1/hu unknown
- 1995-12-21 DK DK95942209T patent/DK0801564T3/da active
-
1997
- 1997-06-26 NO NO19972980A patent/NO315687B1/no not_active IP Right Cessation
- 1997-06-27 FI FI972793A patent/FI118884B/fi not_active IP Right Cessation
-
1998
- 1998-12-21 US US09/217,728 patent/US6075046A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2207333C (en) | 2006-10-17 |
| JPH10511655A (ja) | 1998-11-10 |
| SK85697A3 (en) | 2000-04-10 |
| US5874461A (en) | 1999-02-23 |
| KR100264348B1 (ko) | 2000-08-16 |
| CZ287513B6 (en) | 2000-12-13 |
| ES2176354T3 (es) | 2002-12-01 |
| AU700364B2 (en) | 1999-01-07 |
| NO972980D0 (no) | 1997-06-26 |
| SI0801564T1 (en) | 2002-08-31 |
| HUT77927A (hu) | 1998-11-30 |
| EP0801564B1 (de) | 2002-03-27 |
| AU4347796A (en) | 1996-07-19 |
| CZ191997A3 (cs) | 1999-01-13 |
| DE69526120T2 (de) | 2002-11-28 |
| CN1171739A (zh) | 1998-01-28 |
| NZ298074A (en) | 2001-01-26 |
| NO315687B1 (no) | 2003-10-13 |
| DE69526120D1 (de) | 2002-05-02 |
| EP0801564A1 (de) | 1997-10-22 |
| DK0801564T3 (da) | 2002-07-15 |
| FI972793A (fi) | 1997-06-27 |
| FI118884B (fi) | 2008-04-30 |
| CA2207333A1 (en) | 1996-07-04 |
| US6075046A (en) | 2000-06-13 |
| NO972980L (no) | 1997-06-26 |
| HU226208B1 (en) | 2008-06-30 |
| PT801564E (pt) | 2002-09-30 |
| SK282144B6 (sk) | 2001-11-06 |
| CN1167418C (zh) | 2004-09-22 |
| MX9704669A (es) | 1997-09-30 |
| WO1996019987A1 (en) | 1996-07-04 |
| FI972793A0 (fi) | 1997-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE214924T1 (de) | Verwendung von nebivolol als anti-atherogenisches mittel | |
| TR199901174T2 (xx) | Yeni heterosiklilmetil-ikameli pirazol t�revleri. | |
| TR199901172T2 (xx) | Yeni ikame edilmi� pirazol t�revleri. | |
| DE69920757D1 (de) | Immunsuppressive wirkungen von pteridinderivaten | |
| HUP9700603A1 (hu) | Gyógyászati készítmény véralvadási zavarok kezelésére | |
| EE9900481A (et) | Väikesed molekulid, mida kasutatakse põletikuliste haiguste raviks | |
| DE69725879D1 (de) | VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN | |
| ATE528279T1 (de) | 3-butenyl-1-aminederivate und ihre verwendung als ih modulatoren von therapie für psychiatrische erkrankungen | |
| ATE151774T1 (de) | Cyclopentanperhydrophenanthren-17-beta-(3-furyl - 3-derivate und pharmazeutische präparate davon, zur behandlung von kardiovaskulär-erkrankungen | |
| BG102707A (en) | New triazolopurinpurines, method for their preparation and appplication as medicamentous forms | |
| DE69910425D1 (de) | Neue therapeutische verwendung von nicergoline | |
| AU1569700A (en) | Novel therapeutic application of low molecular weight heparin | |
| NO984651D0 (no) | Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet | |
| TR200003352T2 (tr) | Yeni pentaerythrit türevleri, bunların imalatı ve kullanımları ile bunların sentezi için ara maddeler | |
| ATE225181T1 (de) | Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen | |
| DK0820308T3 (da) | Konjugat til behandling af inflammatoriske sygdomme | |
| NO984198D0 (no) | Fremgangsmåte for behandling av aggresjon | |
| AU1278700A (en) | Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline | |
| MX9706454A (es) | Uso de benzotiazoles fusionados como neuroproyectores. | |
| MX9704733A (es) | Monomeros de ciclohesan-1-ona 4,4-disubstituidos y compuestos relacionados. | |
| MX9704739A (es) | Monomeros de 3,3-(disustituido)ciclohexan-1-ona y compuestos relacionados. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |